US Stock MarketDetailed Quotes
CRVO CervoMed
- 10.800
- +1.645+17.97%
Close Nov 29 13:00 ET
- 11.350
- +0.550+5.09%
Post 17:01 ET
89.14MMarket Cap-7463P/E (TTM)
11.500High9.160Low344.21KVolume9.270Open9.155Pre Close3.59MTurnover8.43%Turnover RatioLossP/E (Static)8.25MShares26.37952wk High1.95P/B44.09MFloat Cap5.85052wk Low--Dividend TTM4.08MShs Float3375000000.000Historical High--Div YieldTTM25.56%Amplitude4.140Historical Low10.442Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
CervoMed Stock Forum
NOTE:
1. Not all of these stocks will go up. Everything relies on market sentiment/buy pressure, the satanic shorts including dark pool.
2. The SI CTB and shorts availability are based on 11/29 data and may get updated Monday.
$PainReform (PRFX.US)$ Microfloat. Up after hours with no catalyst. SI 20%, 0 shares LTB, CTB 642%. May squeeze with buy pressure
$Elevai Labs (ELAB.US)$ Bottoms play. Post ...
$Applied Therapeutics (APLT.US)$ Crashed after FDA CRL but will resubmit. Dropped from 10 to 1.3 rebounded to 1.95. SI 16%
$PainReform (PRFX.US)$ Microfloat. Up after hours. SI 20%. 0 shares LTB. CTB 436%. If there is no catalyst, microfloats will be a quick play.✔️
$Blue Ocean Acquisition Corp (BOCN.US)$ Merger ...
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
CervoMed (NASDAQ: CRVO) announced that its oral drug neflamapimod received Orphan Drug Designation from the FDA for treating frontotemporal dementia (FTD).
The designation applies to therapies for rare diseases affecting fewer than 200,000 people in the US and provides benefits including tax credits, development assistance,...
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
why everything is moving so slow today??
😂 😆
No comment yet